Plain-English translation of NCT06815380 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Atopic Dermatitis research guide βThis trial is studying how lebrikizumab works for adults with moderate-to-severe eczema in real-world everyday medical practice across Europe. Researchers want to understand whether this medication improves not only your skin symptoms, but also your overall well-being, energy levels, work ability, and quality of life. The study will follow you for about two years to see how the treatment affects you over time.
While this medication has been approved for eczema, doctors want to learn more about how it actually helps patients in daily life β including whether it reduces fatigue, helps people work better, and improves their emotional relationship with their skin. This real-world information will help doctors understand how well the treatment works outside of controlled research settings.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will continue taking lebrikizumab as your doctor prescribes it as part of normal care. Researchers will collect information from your medical records and ask you to complete surveys about your well-being, skin symptoms, energy levels, and how your condition affects work and daily life. This data collection will happen over 104 weeks (about 2 years), allowing doctors to track how the treatment helps you over the long term.
AI-generated summary from trial data Β· Jun 3, 2026 Β· Not medical advice
Denmark